Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Quarterly Financial Report Reauthorization Act
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Quarterly Financial Report Reauthorization Act
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ELI LILLY AND COMPANY via ROBERT ARMITAGE
2017 · fourth_quarter · 4T
Biopharmaceutical-related IP protection issues, focused on patents and patent law reform.
Biopharmaceutical-related IP protection issues, with a focus on data package protection regimes.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
Quarterly Financial Report Reauthorization Act
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Quarterly Financial Report Reauthorization Act
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Quarterly Financial Report Reauthorization Act
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Quarterly Financial Report Reauthorization Act
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Quarterly Financial Report Reauthorization Act
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Quarterly Financial Report Reauthorization Act
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Alaska Native Claims Settlement Improvement Act of 2016
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Alaska Native Claims Settlement Improvement Act of 2016
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Alaska Native Claims Settlement Improvement Act of 2016
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Alaska Native Claims Settlement Improvement Act of 2016
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Alaska Native Claims Settlement Improvement Act of 2016
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Alaska Native Claims Settlement Improvement Act of 2016
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Alaska Native Claims Settlement Improvement Act of 2016
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Alaska Native Claims Settlement Improvement Act of 2016
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Quarterly Financial Report Reauthorization Act
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Quarterly Financial Report Reauthorization Act
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Quarterly Financial Report Reauthorization Act
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), and The Innovation Act (H.R. 9, 114th Cong.).
Quarterly Financial Report Reauthorization Act
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.)
Quarterly Financial Report Reauthorization Act
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Quarterly Financial Report Reauthorization Act
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Quarterly Financial Report Reauthorization Act
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Quarterly Financial Report Reauthorization Act
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Quarterly Financial Report Reauthorization Act
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.)
Quarterly Financial Report Reauthorization Act
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), and The Innovation Act (H.R. 9, 114th Cong.).
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Alaska Native Claims Settlement Improvement Act of 2016
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Alaska Native Claims Settlement Improvement Act of 2016
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Alaska Native Claims Settlement Improvement Act of 2016
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.)
Alaska Native Claims Settlement Improvement Act of 2016
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Alaska Native Claims Settlement Improvement Act of 2016
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Alaska Native Claims Settlement Improvement Act of 2016
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Alaska Native Claims Settlement Improvement Act of 2016
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Alaska Native Claims Settlement Improvement Act of 2016
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.)
Alaska Native Claims Settlement Improvement Act of 2016
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), and The Innovation Act (H.R. 9, 114th Cong.).
Alaska Native Claims Settlement Improvement Act of 2016
Client: ELI LILLY AND COMPANY · Firm: ROBERT ARMITAGE
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
2017 · third_quarter · Q3
Biopharmaceutical-related IP protection issues, with a focus on data package protection regimes.
Biopharmaceutical-related IP protection issues, focused on patents and patent law reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via ROBERT ARMITAGE
2017 · second_quarter · Q2
Biopharmaceutical-related IP protection issues, focused on patents and patent law reform.
Biopharmaceutical-related IP protection issues, with a focus on data package protection regimes.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via ROBERT ARMITAGE
2017 · first_quarter · Q1
Biopharmaceutical-related IP protection issues, focused on patents and patent law reform.
Biopharmaceutical-related IP protection issues, with a focus on data package protection regimes.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via ROBERT ARMITAGE
2016 · fourth_quarter · Q4
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via ROBERT ARMITAGE
2016 · third_quarter · Q3
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via ROBERT ARMITAGE
2016 · second_quarter · Q2
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via ROBERT ARMITAGE
2016 · first_quarter · Q1
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via ROBERT ARMITAGE
2015 · fourth_quarter · Q4
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via ROBERT ARMITAGE
2015 · third_quarter · Q3
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via ROBERT ARMITAGE
2015 · second_quarter · Q2
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via ROBERT ARMITAGE
2015 · first_quarter · Q1
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), and The Innovation Act (H.R. 9, 114th Cong.).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via ROBERT ARMITAGE
2015 · first_quarter · RR
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.)
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.)
ELI LILLY AND COMPANY via ROBERT ARMITAGE
2014 · fourth_quarter · Q4
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via ROBERT ARMITAGE
2014 · third_quarter · Q3
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via ROBERT ARMITAGE
2014 · second_quarter · Q2
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via ROBERT ARMITAGE
2014 · first_quarter · Q1
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.)and Dormant Therapies Act (S. 3004, 113th Cong.)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE